» Articles » PMID: 28881874

Oncopression: Gene Expression Compendium for Cancer with Matched Normal Tissues

Overview
Journal Bioinformatics
Specialty Biology
Date 2017 Sep 9
PMID 28881874
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Motivation: Expression profile of normal tissue is primary source to find genes showing aberrant expression pattern specific in matched cancer tissue, but sample number of normal control in public gene expression repositories is disproportionally small compared to cancer and scattered in several datasets.

Results: We built oncopression by integrating several datasets into one large dataset for comprehensive analysis about 25 types of human cancers including 20 640 cancer samples and 6801 normal control profiles. Expression profiles in cancers can be directly compared to normal tissue counterparts. Validity of the integration was tested using immunohistochemical staining results and principal component analysis. We have utilized the pre-release version of oncopression to identify cancer-specific genes in several studies.

Availability And Implementation: Free access at http://www.oncopression.com and all expression data are available for download at the site.

Contacts: cchoi@kaist.ac.kr or jungsullee@gmail.com.

Supplementary Information: Supplementary data are available at Bioinformatics online.

Citing Articles

Application of Transcriptome-Based Gene Set Featurization for Machine Learning Model to Predict the Origin of Metastatic Cancer.

Jeong Y, Chu J, Kang J, Baek S, Lee J, Jung D Curr Issues Mol Biol. 2024; 46(7):7291-7302.

PMID: 39057073 PMC: 11276602. DOI: 10.3390/cimb46070432.


Identifying the role of MTHFD1L in prostate cancer progression from genetic analysis and experimental validation.

Tsai Y, Huang S, Cheng W, Fan Y, Lin Y, Tsai S Am J Cancer Res. 2024; 14(1):169-181.

PMID: 38323273 PMC: 10839318.


Regnase-2 inhibits glioblastoma cell proliferation.

Sowinska W, Wawro M, Kochan J, Solecka A, Polak J, Kwinta B Sci Rep. 2024; 14(1):1574.

PMID: 38238463 PMC: 10796923. DOI: 10.1038/s41598-024-51809-x.


Fibronectin Type III Domain Containing 3B as a Potential Prognostic and Therapeutic Biomarker for Glioblastoma.

Kwon H, Yun M, Kwon T, Bang M, Lee J, Lee Y Biomedicines. 2023; 11(12).

PMID: 38137388 PMC: 10741045. DOI: 10.3390/biomedicines11123168.


Molecular and Metabolic Phenotyping of Hepatocellular Carcinoma for Biomarker Discovery: A Meta-Analysis.

Anh N, Long N, Min Y, Ki Y, Kim S, Jung C Metabolites. 2023; 13(11).

PMID: 37999208 PMC: 10672761. DOI: 10.3390/metabo13111112.